Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Hexarelin (GH Secretagogue Hexapeptide)
Also known as: Examorelin, HEX
Confidence
Updated 2026-03-18
Hexarelin is a synthetic hexapeptide growth hormone secretagogue and one of the most potent GHRPs studied. It stimulates GH release via the ghrelin receptor and has unique cardioprotective properties independent of its GH-releasing activity. Despite promising research, it was never brought to market due to tachyphylaxis (reduced response with repeated dosing).
Class
GH Secretagogue (GHRP)
Routes
Subcutaneous, Intranasal, Intravenous
Half-Life
~70 minutes
Hexarelin binds the GHS-R1a (ghrelin receptor) and a distinct cardiac receptor (CD36/SR-B1) to stimulate GH release from the pituitary. Unlike GHRP-6, it has relatively modest effects on appetite. Its cardioprotective effects are mediated through CD36 receptor activation, reducing cardiac fibrosis, improving ventricular function, and protecting against ischemia-reperfusion injury independently of GH elevation.
Half-Life
~70 minutes
Bioavailability
Subcutaneous: ~75% (estimated); Intranasal: ~10–20%
No approved indications. Research contexts: GH deficiency assessment (diagnostic), cardioprotection, cachexia, body composition optimization.
Human studies demonstrated potent GH release (greatest GH spike of all GHRPs), but significant tachyphylaxis develops within 4–16 weeks of continuous use. Cardioprotective effects demonstrated in both animal and small human studies — improved ejection fraction in GH-deficient adults. Italian research group published most clinical data.
Human Studies
15
Animal Studies
40
Generally well-tolerated acutely. May increase cortisol and prolactin (more than ipamorelin). Flushing, dizziness. Tachyphylaxis is the primary limitation. Theoretical concern about IGF-1 elevation and cancer risk with chronic use.
Investigational. No active clinical development programs. Available through research chemical suppliers.
Drug Interactions: May interact with corticosteroids. Caution with drugs affecting cardiac conduction. Monitoring: GH, IGF-1, cortisol, prolactin. Research Gaps: No long-term human safety data. Tachyphylaxis limits clinical utility. Cardioprotective applications remain unexplored in large trials.
Subcutaneous (research context)
Common Range
100–300 mcg/dose
Timing
Morning fasted or pre-bedtime
Frequency
1–3 times daily
Cycling
4–8 weeks on, 4 weeks off (mandatory due to desensitization)
Reconstitution
Reconstitute lyophilized powder with bacteriostatic water
Storage
Refrigerated after reconstitution
Important Note
NOT FDA-approved. Tachyphylaxis develops rapidly — must be cycled. More potent GH release than ipamorelin but more side effects.
Connect with a verified provider offering Hexarelin therapy near you.
GH Secretagogue
Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to stimulate GH release from the pituitary. It is considered one of the most selective GH secretagogues, with minimal effect on cortisol, prolactin, and other hormones — making it a preferred choice in combination protocols with CJC-1295.
GH Secretagogue (GHRP)
GHRP-6 is a synthetic hexapeptide that potently stimulates growth hormone release via the ghrelin receptor. It was one of the earliest GHRPs discovered and is notable for its strong appetite-stimulating effects (mediated by ghrelin pathway activation). It has been widely used in research settings for GH axis assessment and body composition studies.
GH Secretagogue (GHRP)
GHRP-2 is a synthetic hexapeptide GH secretagogue considered the most potent GHRP in terms of GH release per dose. It is approved in Japan as a diagnostic agent for GH deficiency (under the name Pralmorelin). It provides a strong GH stimulus with moderate appetite effects — positioned between the hunger-inducing GHRP-6 and the clean-profile ipamorelin.
GHRH Analog
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid GHRH sequence. Originally FDA-approved for diagnostic use in assessing growth hormone secretion, it has become a cornerstone of legitimate peptide therapy for growth hormone optimization due to its established safety profile and compounding eligibility.
GH Secretagogue
CJC-1295 is a synthetic analog of GHRH(1-29) with modifications to extend its half-life. Available in two forms: with Drug Affinity Complex (DAC) for prolonged action, and without DAC (also called Modified GRF 1-29) for shorter, more pulsatile action. Frequently combined with ipamorelin for synergistic GH release.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.